Long-term efficacy of brodalumab in ustekinumab-responsive patients with moderate-to-severe psoriasis

被引：0
|
作者：
Green, Lawrence [1 ]
Hsu, Sylvia [2 ]
Papp, Kim A. [3 ]
Rastogi, Shipra [4 ]
Pillai, Radhakrishnan [5 ]
Israel, Robert J. [6 ]
机构：
[1] George Washington Univ, Sch Med, Washington, DC 20052 USA
[2] Temple Univ, Sch Med, Philadelphia, PA 19122 USA
[3] Prob Med Res, Waterloo, ON, Canada
[4] Ortho Dermatol, Bridgewater, MA USA
[5] Dow Pharmaceut Sci, Petaluma, CA USA
[6] Valeant Pharmaceut North Amer, Bridgewater, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
6832
引用
收藏
页码：AB181 / AB181
页数：1
相关论文
共 50 条
  • [31] LONG-TERM TREATMENT PATTERNS AMONG PATIENTS WHO DEVELOPED MODERATE-TO-SEVERE PSORIASIS
    Feldman, S. R.
    Zhao, Y.
    Hur, P.
    Liu, J. S.
    Herrera, V
    VALUE IN HEALTH, 2017, 20 (05) : A162 - A162
  • [32] A NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY OF BRODALUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
    Sawyer, L.
    Fotheringham, I
    Wright, E.
    Bermingham, S.
    Gibbons, C.
    Moller, A. H.
    Marques, R.
    VALUE IN HEALTH, 2017, 20 (09) : A801 - A801
  • [33] Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain
    Sanga, Panna
    Katz, Nathaniel
    Polverejan, Elena
    Wang, Steven
    Kelly, Kathleen M.
    Haeussler, Juergen
    Thipphawong, John
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (04) : 763 - 773
  • [34] A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis
    Roostaeyan, Omid
    Kivelevitch, Dario
    Menter, Alan
    IMMUNOTHERAPY, 2017, 9 (12) : 963 - 978
  • [35] Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis
    Cao, Zhun
    Carter, Chureen
    Wilson, Kathleen L.
    Schenkel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (02) : 113 - 120
  • [36] The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients
    Young, Melodie S.
    Horn, Elizabeth J.
    Cather, Jennifer C.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (01) : 9 - 13
  • [37] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [38] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [39] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [40] Long-term efficacy and safety of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 7 years in a real world setting: The experience of a reference Hospital in the Canary Islands
    Guimera-Martin-Neda, Francisco
    Garcia-Bustinduy, Marta
    Fagundo-Gonzalez, Eva
    Andres-Rosario, Ana
    Pestana-Eliche, Maria
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB233 - AB233
12345